| HOME >> MEDICINE >> TECHNOLOGY |
5. The Ophthalmic Anti-Allergy/Inflammatory/Infective Drug Market, 2012-2022
5.1 The Ophthalmic Anti-Allergy/Inflammatory/ Infective Market in 2010
5.1.1 Patanol
5.1.2 Vigamox/Vegamox
5.1.3 TobraDex
5.1.4 Pataday
5.1.5 Cravit
5.1.6 Acular
5.1.7 Xibrom/Bromday
5.2 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecasts, 2012-2022
5.2.1 Innovation in the Anti-Allergy/Inflammatory/Infective R&D Pipeline
5.2.2 Patanol Sales Forecast, 2012-2022
5.2.3 Vigamox Sales Forecast, 2012-2022
5.2.4 TobraDex Sales Forecast, 2012-2022
5.2.5 Pataday Sales Forecast, 2012-2022
5.2.6 Cravit Sales Forecast, 2012-2022
5.2.7 Acular Sales Forecast, 2012-2022
5.2.8 Xibrom/Bromday Sales Forecast, 2012-2022
6. The Retinal Disorders Drug Market, 2012-20226.1 The Retinal Disorder Treatment Market6.1.1 Wet AMD has the Largest Market Share of the Retinal Disorders Market6.1.2 Lucentis Took Control of the Retinal Disorder Market in 20106.1.3 Visudyne was the Second Highest Selling Retinal Disorder Drug in 20096.1.4 Lucentis has Sidelined Macugen but Faces Potent Threat from Avastin6.1.5 Allergan's Ozurdex, First Drug Therapy for Macular Oedema6.2 Retinal Disorder Market Forecasts, 2012-20226.2.1 Lucentis Will Drive the Retinal Disorder Market from 2010-20166.2.2 Novel Drugs and New Disease Treatments Will Drive Growth from 2017-20226.2.3 Lucentis Sales Forecast, 2012-20226.2.4 Visudyne Sales Forecast, 2012-2022
7. The Dry Eye Drug Market, 2012-2022
7.1 The Dry Eye Drug Market in 2010
7.1.1 Restasis - Prescription Drug for Dry Eye
7.1.2 Allergan's Refresh Brand, including Celluvisc, is the Second-Best-Selling Dry Eye Product
7.1.3 Hyalein: Marketed in Japan and China
7.1.4 The OTC Market for Artificial Tears is Fragmented and Competitive
<| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |